{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-347897","form_type":"8-K","ticker":"KPTI","cik":"0001503802","company_name":"Karyopharm Therapeutics Inc.","filed_at":"2026-08-13T11:37:30+00:00","discovered_at":"2026-08-13T11:40:00.320411+00:00","generated_at":"2026-08-13T11:40:07.437833+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Karyopharm Q2 net loss $67M; cash runway only to Sept 2026, sNDA on track","bullets":["Q2 2026 total revenue $33.4M (vs $37.9M YoY); U.S. XPOVIO net product revenue $30.8M (vs $29.7M).","Net loss $67.0M ($2.32/share) vs $37.3M loss ($4.32/share) in Q2 2025; operating loss $22.5M.","Cash $65.4M at June 30; expects funding only into Sept 2026; $15.8M term loan payment due Sept 10, 2026 may trigger default.","Planned August sNDA for selinexor+ruxolitinib in myelofibrosis under Accelerated Approval; FDA feedback supports SVR35 as surrogate.","Phase 3 XPORT-EC-042 endometrial trial missed primary endpoint (PFS); median PFS 12.75 vs 7.43 months, HR 0.76, p=0.0791."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-347897","json":"https://secwatch.observer/filing/0001193125-26-347897.json","markdown":"https://secwatch.observer/filing/0001193125-26-347897.md","text":"https://secwatch.observer/filing/0001193125-26-347897.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/0001193125-26-347897-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1503802/000119312526347897/kpti-20260813.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-13T11:40:07.437833+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}